A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer

Nur Vaizura Mohamad, Ima Nirwana Soelaiman, Chin Kok Yong

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

BACKGROUND AND OBJECTIVE: Prostate cancer is the most prevalent non-cutaneous cancer in men, which causes significant mortality among the patients. Since prostate cancer cells are stimulated by androgen, effective androgen ablation in men is one of the essential strategies in the management of prostate cancer.

DISCUSSION: Several treatment options are available for different stages of prostate cancer. Hormone therapy known as androgen deprivation therapy (ADT) is the first line treatment used to treat advanced prostate cancer. Chemical castration by gonadotropin-releasing hormone agonists suppresses lutenizing hormone production, which in turn inhibits the production of testosterone and dihydrotestosterone. This will prevent the growth of prostate cancer cells. However, ADT causes deleterious effects on bone health because the androgens are essential in preserving optimal bone health in men.

CONCLUSION: Various observational studies showed that long-term ADT for advanced or metastatic prostate cancer was associated with decreased bone mineral density, as well as altered body composition that might affect bone health. Considering the potential impact of osteoporotic fracture, interventions to mitigate these skeletal adverse effects should be considered by physicians when initiating ADT on their patients.

Original languageEnglish
Pages (from-to)276-284
Number of pages9
JournalEndocrine, metabolic & immune disorders drug targets
Volume17
Issue number4
DOIs
Publication statusPublished - 16 Nov 2017

Fingerprint

Androgens
Health Status
Prostatic Neoplasms
Bone and Bones
Therapeutics
Men's Health
Osteoporotic Fractures
Dihydrotestosterone
Castration
Health
Luteinizing Hormone
Body Composition
Gonadotropin-Releasing Hormone
Bone Density
Observational Studies
Testosterone
Hormones
Physicians
Mortality
Growth

Keywords

  • androgen deprivation therapy
  • bone health
  • bone mineral density (BMD)
  • Prostate cancer
  • radiotherapy
  • testosterone

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy

Cite this

@article{18d9eabd2e2b4221b0a85e3473bd4cb2,
title = "A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer",
abstract = "BACKGROUND AND OBJECTIVE: Prostate cancer is the most prevalent non-cutaneous cancer in men, which causes significant mortality among the patients. Since prostate cancer cells are stimulated by androgen, effective androgen ablation in men is one of the essential strategies in the management of prostate cancer.DISCUSSION: Several treatment options are available for different stages of prostate cancer. Hormone therapy known as androgen deprivation therapy (ADT) is the first line treatment used to treat advanced prostate cancer. Chemical castration by gonadotropin-releasing hormone agonists suppresses lutenizing hormone production, which in turn inhibits the production of testosterone and dihydrotestosterone. This will prevent the growth of prostate cancer cells. However, ADT causes deleterious effects on bone health because the androgens are essential in preserving optimal bone health in men.CONCLUSION: Various observational studies showed that long-term ADT for advanced or metastatic prostate cancer was associated with decreased bone mineral density, as well as altered body composition that might affect bone health. Considering the potential impact of osteoporotic fracture, interventions to mitigate these skeletal adverse effects should be considered by physicians when initiating ADT on their patients.",
keywords = "androgen deprivation therapy, bone health, bone mineral density (BMD), Prostate cancer, radiotherapy, testosterone",
author = "Mohamad, {Nur Vaizura} and Soelaiman, {Ima Nirwana} and {Kok Yong}, Chin",
year = "2017",
month = "11",
day = "16",
doi = "10.2174/1871530317666170919112757",
language = "English",
volume = "17",
pages = "276--284",
journal = "Endocrine, Metabolic and Immune Disorders - Drug Targets",
issn = "1871-5303",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer

AU - Mohamad, Nur Vaizura

AU - Soelaiman, Ima Nirwana

AU - Kok Yong, Chin

PY - 2017/11/16

Y1 - 2017/11/16

N2 - BACKGROUND AND OBJECTIVE: Prostate cancer is the most prevalent non-cutaneous cancer in men, which causes significant mortality among the patients. Since prostate cancer cells are stimulated by androgen, effective androgen ablation in men is one of the essential strategies in the management of prostate cancer.DISCUSSION: Several treatment options are available for different stages of prostate cancer. Hormone therapy known as androgen deprivation therapy (ADT) is the first line treatment used to treat advanced prostate cancer. Chemical castration by gonadotropin-releasing hormone agonists suppresses lutenizing hormone production, which in turn inhibits the production of testosterone and dihydrotestosterone. This will prevent the growth of prostate cancer cells. However, ADT causes deleterious effects on bone health because the androgens are essential in preserving optimal bone health in men.CONCLUSION: Various observational studies showed that long-term ADT for advanced or metastatic prostate cancer was associated with decreased bone mineral density, as well as altered body composition that might affect bone health. Considering the potential impact of osteoporotic fracture, interventions to mitigate these skeletal adverse effects should be considered by physicians when initiating ADT on their patients.

AB - BACKGROUND AND OBJECTIVE: Prostate cancer is the most prevalent non-cutaneous cancer in men, which causes significant mortality among the patients. Since prostate cancer cells are stimulated by androgen, effective androgen ablation in men is one of the essential strategies in the management of prostate cancer.DISCUSSION: Several treatment options are available for different stages of prostate cancer. Hormone therapy known as androgen deprivation therapy (ADT) is the first line treatment used to treat advanced prostate cancer. Chemical castration by gonadotropin-releasing hormone agonists suppresses lutenizing hormone production, which in turn inhibits the production of testosterone and dihydrotestosterone. This will prevent the growth of prostate cancer cells. However, ADT causes deleterious effects on bone health because the androgens are essential in preserving optimal bone health in men.CONCLUSION: Various observational studies showed that long-term ADT for advanced or metastatic prostate cancer was associated with decreased bone mineral density, as well as altered body composition that might affect bone health. Considering the potential impact of osteoporotic fracture, interventions to mitigate these skeletal adverse effects should be considered by physicians when initiating ADT on their patients.

KW - androgen deprivation therapy

KW - bone health

KW - bone mineral density (BMD)

KW - Prostate cancer

KW - radiotherapy

KW - testosterone

UR - http://www.scopus.com/inward/record.url?scp=85045216817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045216817&partnerID=8YFLogxK

U2 - 10.2174/1871530317666170919112757

DO - 10.2174/1871530317666170919112757

M3 - Review article

C2 - 28925899

AN - SCOPUS:85045216817

VL - 17

SP - 276

EP - 284

JO - Endocrine, Metabolic and Immune Disorders - Drug Targets

JF - Endocrine, Metabolic and Immune Disorders - Drug Targets

SN - 1871-5303

IS - 4

ER -